An increasing number of clinical trials have been underway since 2011 to assess the potential therapeutic efficacy of PD-1/PD-L1 and CTLA-4 inhibitors as monotherapies and combination therapies for GBM (71). Here, PDCD1 is linked to glioblastoma.